company background image
BBLG

Bone Biologics NasdaqCM:BBLG Stock Report

Last Price

US$1.15

Market Cap

US$11.9m

7D

9.5%

1Y

n/a

Updated

27 Sep, 2022

Data

Company Financials +
BBLG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BBLG Stock Overview

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.

Bone Biologics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bone Biologics
Historical stock prices
Current Share PriceUS$1.15
52 Week HighUS$7.12
52 Week LowUS$1.05
Beta0.31
1 Month Change-14.18%
3 Month Change-20.14%
1 Year Changen/a
3 Year Change-94.59%
5 Year Change-99.12%
Change since IPO-98.88%

Recent News & Updates

Mar 18
We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

BBLGUS BiotechsUS Market
7D9.5%-3.3%-5.8%
1Yn/a-27.4%-22.1%

Return vs Industry: Insufficient data to determine how BBLG performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how BBLG performed against the US Market.

Price Volatility

Is BBLG's price volatile compared to industry and market?
BBLG volatility
BBLG Average Weekly Movement14.1%
Biotechs Industry Average Movement11.0%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: BBLG is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: BBLG's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20042Jeff Frelickhttps://www.bonebiologics.com

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1.

Bone Biologics Fundamentals Summary

How do Bone Biologics's earnings and revenue compare to its market cap?
BBLG fundamental statistics
Market CapUS$11.90m
Earnings (TTM)-US$1.85m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BBLG income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$1.85m
Earnings-US$1.85m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.18
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did BBLG perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BBLG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BBLG?

Other financial metrics that can be useful for relative valuation.

BBLG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does BBLG's PB Ratio compare to its peers?

BBLG PB Ratio vs Peers
The above table shows the PB ratio for BBLG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.9x
PHGE BiomX
0.3x1.1%US$10.0m
ALLR Allarity Therapeutics
1.5x1.8%US$12.0m
PTIX Protagenic Therapeutics
1.3xn/aUS$10.6m
DFFN Diffusion Pharmaceuticals
0.4x15.3%US$11.1m
BBLG Bone Biologics
2.1xn/aUS$11.9m

Price-To-Book vs Peers: BBLG is expensive based on its Price-To-Book Ratio (2.1x) compared to the peer average (0.9x).


Price to Earnings Ratio vs Industry

How does BBLG's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: BBLG is expensive based on its Price-To-Book Ratio (2.1x) compared to the US Biotechs industry average (1.5x)


Price to Book Ratio vs Fair Ratio

What is BBLG's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BBLG PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BBLG's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BBLG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BBLG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BBLG's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Bone Biologics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BBLG's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if BBLG's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if BBLG's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BBLG's revenue is forecast to grow faster than the US market.

High Growth Revenue: BBLG is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BBLG's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Bone Biologics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


45.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BBLG is currently unprofitable.

Growing Profit Margin: BBLG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BBLG is unprofitable, but has reduced losses over the past 5 years at a rate of 45.6% per year.

Accelerating Growth: Unable to compare BBLG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BBLG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: BBLG has a negative Return on Equity (-33.03%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Bone Biologics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BBLG's short term assets ($5.7M) exceed its short term liabilities ($70.6K).

Long Term Liabilities: BBLG's short term assets ($5.7M) exceed its long term liabilities ($10.0).


Debt to Equity History and Analysis

Debt Level: BBLG is debt free.

Reducing Debt: BBLG currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BBLG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BBLG has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 29.7% each year.


Discover healthy companies

Dividend

What is Bone Biologics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Bone Biologics Dividend Yield vs Market
How does Bone Biologics dividend yield compare to the market?
SegmentDividend Yield
Company (Bone Biologics)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Bone Biologics)n/a

Notable Dividend: Unable to evaluate BBLG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BBLG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BBLG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BBLG's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BBLG has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.8yrs

Average management tenure


CEO

Jeff Frelick (56 yo)

3.25yrs

Tenure

US$290,000

Compensation

Mr. Jeffrey Frelick, also known as Jeff, has been the President and Chief Executive Officer at Bone Biologics Corporation since June 28, 2019. He served as Chief Operating Officer at Bone Biologics, Corp....


CEO Compensation Analysis

Jeff Frelick's Compensation vs Bone Biologics Earnings
How has Jeff Frelick's remuneration changed compared to Bone Biologics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$2m

Mar 31 2022n/an/a

-US$2m

Dec 31 2021US$290kUS$245k

-US$2m

Sep 30 2021n/an/a

-US$2m

Jun 30 2021n/an/a

-US$2m

Mar 31 2021n/an/a

-US$2m

Dec 31 2020US$300kUS$240k

-US$2m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$3m

Dec 31 2019US$300kUS$240k

-US$3m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$300kUS$240k

-US$4m

Sep 30 2018n/an/a

-US$6m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$6m

Dec 31 2017US$300kUS$240k

-US$7m

Sep 30 2017n/an/a

-US$14m

Jun 30 2017n/an/a

-US$16m

Mar 31 2017n/an/a

-US$22m

Dec 31 2016US$771kUS$288k

-US$26m

Sep 30 2016n/an/a

-US$24m

Jun 30 2016n/an/a

-US$23m

Mar 31 2016n/an/a

-US$19m

Dec 31 2015US$2mUS$113k

-US$14m

Compensation vs Market: Jeff's total compensation ($USD290.00K) is below average for companies of similar size in the US market ($USD787.63K).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BBLG's management team is seasoned and experienced (7.8 years average tenure).


Board Members

Experienced Board: BBLG's board of directors are considered experienced (9.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of BBLG?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders129,7521.3%
Institutions289,9242.8%
General Public2,855,40627.6%
Private Companies7,075,49768.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 9 shareholders own 72.41% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
68.05%
Hankey Capital, LLC
7,043,801$8.1m0%no data
2.29%
The Musculoskeletal Transplant Foundation, Inc., Endowment Arm
236,679$272.2k0%no data
1.22%
Don Hankey
126,656$145.7k0%no data
0.32%
The Vanguard Group, Inc.
33,461$38.5k0%no data
0.31%
AFH Holding & Advisory, LLC
31,696$36.5k0%no data
0.074%
UBS Asset Management
7,673$8.8k8927.06%no data
0.06%
Tower Research Capital LLC
6,165$7.1k0%no data
0.057%
Geode Capital Management, LLC
5,946$6.8k1.52%no data
0.03%
Jeffrey Frelick
3,096$3.6k0%no data

Company Information

Bone Biologics Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Bone Biologics Corporation
  • Ticker: BBLG
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$11.903m
  • Shares outstanding: 10.35m
  • Website: https://www.bonebiologics.com

Number of Employees


Location

  • Bone Biologics Corporation
  • 2 Burlington Woods Drive
  • Suite 100
  • Burlington
  • Massachusetts
  • 1803
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BBLGNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2015

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/27 00:00
End of Day Share Price2022/09/27 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.